Generating evidence for therapeutic effects: the need for well-conducted randomized trials.

In this viewpoint, Robert Califf, former commissioner of the U.S. Food and Drug Administration, and colleagues reflect on how to approach questions about which patient treatments and strategies work, particularly in light of the tremendous pressure on the government and biomedical research enterprise to quickly develop safe, effective therapies during the SARS-CoV-2 pandemic.

[1]  Deepak L. Bhatt,et al.  Randomized Trials Versus Common Sense and Clinical Observation , 2020, Journal of the American College of Cardiology.

[2]  Jennifer L. Bell,et al.  Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial. , 2020, medRxiv.

[3]  Philip R Krause,et al.  Creating a Framework for Conducting Randomized Clinical Trials during Disease Outbreaks. , 2020, The New England journal of medicine.

[4]  Rachel L. Richesson,et al.  Developing and Refining the Research Questions , 2017 .

[5]  Emily R. Busta,et al.  Integrating Clinical Research into Epidemic Response: The Ebola Experience , 2017 .

[6]  Robert Platt,et al.  Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses. , 2016, Journal of clinical epidemiology.

[7]  J. Johnston,et al.  A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results , 2015, Trials.

[8]  Jeremy Sugarman,et al.  Ethics and regulatory complexities for pragmatic clinical trials. , 2014, JAMA.

[9]  Steven N Goodman,et al.  An ethics framework for a learning health care system: a departure from traditional research ethics and clinical ethics. , 2013, The Hastings Center report.

[10]  Robert M Califf,et al.  Characteristics of clinical trials registered in ClinicalTrials.gov, 2007-2010. , 2012, JAMA.

[11]  S. Normand,et al.  Reduction in acute myocardial infarction mortality in the United States: risk-standardized mortality rates from 1995-2006. , 2009, JAMA.

[12]  Peter Sandercock,et al.  Sensible approaches for reducing clinical trial costs , 2008, Clinical trials.